The clinical trial application for its shingles mRNA vaccine has been officially accepted
January 19, 2026
Source: drugdu
30
Securities Daily Online – January 16, 2026 – Zhifei Biologics stated on an interactive investor platform today that the company has established multiple technology platforms, including mRNA and novel adjuvant platforms. These are used to explore various vaccine development pathways to achieve product iterations and innovative breakthroughs.
Its wholly-owned subsidiary, Zhifei Longcom, has officially received the Acceptance Notice for its Investigational New Drug (IND) application for a shingles mRNA vaccine from the National Medical Products Administration (NMPA). For further details, please refer to the "Announcement on the Acceptance of the Clinical Trial Application for Shingles mRNA Vaccine" (No. 2025-67).
https://finance.eastmoney.com/a/202601163622203690.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- Lunan Pharmaceutical’s Jiali® Oxaliplatin Injection Receives US Marketing Approval January 19, 2026
- The second NDA for gumozymab, a new drug application for the treatment of ankylosing spondylitis, has been accepted January 19, 2026
- 3.1 billion! Orthopedic giant announces major acquisition. January 19, 2026
- The Small Nucleic Acid Track is Ushering in a Major Explosion January 19, 2026
- Zhong Sheng Pharmaceutical’s groundbreaking innovative drug joins forces with Qilu Pharmaceutical to target a market worth tens of billions of yuan January 19, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
